MX2024000591A - Metodos de tratamiento de enfermedades neurologicas. - Google Patents

Metodos de tratamiento de enfermedades neurologicas.

Info

Publication number
MX2024000591A
MX2024000591A MX2024000591A MX2024000591A MX2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A MX 2024000591 A MX2024000591 A MX 2024000591A
Authority
MX
Mexico
Prior art keywords
methods
neurological diseases
treating neurological
antibodies
treating
Prior art date
Application number
MX2024000591A
Other languages
English (en)
Spanish (es)
Inventor
Shui- On Leung
Chiho Chong
Chingyi Chuang
Original Assignee
Sinomab Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinomab Bioscience Ltd filed Critical Sinomab Bioscience Ltd
Publication of MX2024000591A publication Critical patent/MX2024000591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2024000591A 2021-07-13 2022-07-12 Metodos de tratamiento de enfermedades neurologicas. MX2024000591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163221261P 2021-07-13 2021-07-13
PCT/CN2022/105077 WO2023284710A1 (en) 2021-07-13 2022-07-12 Methods of treating neurological diseases

Publications (1)

Publication Number Publication Date
MX2024000591A true MX2024000591A (es) 2024-03-19

Family

ID=84919904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000591A MX2024000591A (es) 2021-07-13 2022-07-12 Metodos de tratamiento de enfermedades neurologicas.

Country Status (10)

Country Link
US (1) US20240309089A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370153A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527401A (cg-RX-API-DMAC7.html)
KR (1) KR20240042443A (cg-RX-API-DMAC7.html)
CN (1) CN117999096A (cg-RX-API-DMAC7.html)
AU (1) AU2022310081A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225077A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000591A (cg-RX-API-DMAC7.html)
WO (1) WO2023284710A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202400405B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099707A1 (en) * 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
WO2024197258A1 (en) * 2023-03-23 2024-09-26 Klaritos, Inc Methods of treating alzheimer's disease
WO2025190311A1 (en) * 2024-03-12 2025-09-18 Sinomab Bioscience Limited Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9066928B1 (en) * 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9908933B2 (en) * 2013-08-05 2018-03-06 St. Vincent's Institute Of Medical Research Antibody therapy for amyloid beta disease
WO2017196432A1 (en) * 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer

Also Published As

Publication number Publication date
US20240309089A1 (en) 2024-09-19
EP4370153A1 (en) 2024-05-22
JP2024527401A (ja) 2024-07-24
CA3225077A1 (en) 2023-01-19
WO2023284710A1 (en) 2023-01-19
ZA202400405B (en) 2025-03-26
EP4370153A4 (en) 2025-05-07
AU2022310081A1 (en) 2024-02-01
KR20240042443A (ko) 2024-04-02
CN117999096A (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
DE60045427D1 (de) Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen
MXPA03010911A (es) Anticuerpos contra ngf para el tratamiento de varios desordenes.
PL1613347T3 (pl) Humanizowane przeciwciała rozpoznające peptyd beta amyloidowy
AU2782499A (en) Isolated stromal cells for use in the treatment of diseases of the central nervous system
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
MX2025001590A (es) Proteinas y conjugados de union al receptor de transferrina
DK1385864T3 (da) Anti-VEGF-2-antistoffer
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
MY176959A (en) Humanized antibodies that recognize beta amyloid peptide
BRPI0514199A (pt) método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7
JOP20210324A1 (ar) مشتقات من 2h-indazole واستخدامها في علاج مرض
MY208067A (en) Tubulysins and protein-tubulysin conjugates
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2022008320A (es) Métodos para tratar trastornos de pénfigo.
SA521430793B1 (ar) أجسام مضادة مضادة لسيما 3أ واستخداماتها في علاج أمراض العين أو البصر
AU2003291287A8 (en) Apkc isoforms in nervous system disorders and cancer
EP4370131A4 (en) METHODS FOR TREATING ALZHEIMER'S DISEASE
CR20220531A (es) Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
DE60039579D1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
Arenas et al. Oncology: management of elderly cancer patients
SA522432069B1 (ar) Nrp1a أجسام مضادة لـ واستخداماتها لعلاج العين أو أمراض العين
EP4161623C0 (en) AUDIO SYSTEM FOR AUDITORY STIMULATION FOR THE TREATMENT OF NEUROLOGICAL, PSYCHOLOGICAL OR PSYCHIATRIC DISORDERS
PH12021553196A1 (en) Methods for treating neurodegenerative disorders